The effect of magnesium supplements on polycystic ovarian syndrome (PCOS)
Phase 3
- Conditions
- polycystic ovarian syndrome (PCOS).
- Registration Number
- IRCT20200115046147N1
- Lead Sponsor
- Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
1. Patients with polycystic ovary syndrome based on the Rotterdam Diagnostic Criteria2. Satisfaction with attending the study3. Satisfaction to continue cooperation4. Magnesium does not have a high base normal.5. There is no history of electrolyte abnormalities associated with potassium or calcium in the patient.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in Insulin Resistance Index (HOMA-IR). Timepoint: FBS and serum insulin are re-administered to patients at baseline and after 2 months of treatment (end of treatment). Method of measurement: ice.Patients receive fasting insulin for a 12-hour fasting blood sample to measure fasting blood sugar (for diabetes screening).
- Secondary Outcome Measures
Name Time Method